Atrial fibrillation and risk of pulmonary arterial hypertension. Swedisk nationwide registry study

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Bjorn Hornestam

Sahlgrenska Academy, Gothenburg (Sweden)

6 More presentations in this session

Presentation thumbnail

Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study

Miss B. Nguyen (Groningen, NL)

Abstract Slides

Presentation thumbnail

SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation.

Doctor R. Nishinarita (Tokyo, JP)

Abstract Slides

Presentation thumbnail

Association of left atrial size with ischemic and bleeding risk scores in patients with non-valvular atrial fibrillation

Doctor L. Enriquez Rodriguez (Soria, ES)

Abstract Slides

Presentation thumbnail

How could non-vitamin k antagonist oral anticoagulants change clinical practice for stroke prevention and improve outcomes in patients with newly-diagnosed atrial fibrillation?

Doctor T. Chao (Taipei, TW)

Presentation thumbnail

High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI

Doctor R. De Caterina (Pisa, IT)

Abstract Slides

Access the full session

Session thumbnail

Atrial fibrillation - General 2

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

Interactive discussion and Q&A

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - discussion

Congress Presentation

Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources